Clinical trials: bipolar
Depression, Bipolar Disorder
Insulin Resistance in Patients With Mood Disorder
Insulin resistance is known to be associated with mood disorders and cognitive difficulties. The purpose of this study is to treat depressed patients with rosiglitazone (also known as [AKA] Avandia), therefore improving glucose…
- Conditions
- Depression, Bipolar Disorder, Insulin Resistance
- Trial name
- NCT00242619
- Testing
- rosiglitazone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Depression
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major…
- Trial name
- NCT01072929
- Testing
- Armodafinil
- Where
- 40 sites in United States
- Volunteers
- 433 people
- Sponsor
- Cephalon
Bipolar Disorder, Major Depression
Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI
The purpose of the study is to find out what parts of the brain have increased or decreased activity and connectivity in individuals who have bipolar disorder, major depression, or no history of mood disorder.
- Trial name
- NCT01811147
- Testing
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Bipolar Depression
Riluzole in the Treatment of Bipolar Depression
Bipolar disorder is a common and often chronic and debilitating mental illness. The depressive phase of bipolar disorder contributes the largest portion of the disorder, and treatment resistant bipolar depression represents a…
- Trial name
- NCT00544544
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mclean Hospital
Bipolar I Depression
Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine if armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy for adults who are experiencing a major depressive episode…
- Trial name
- NCT00481195
- Testing
- Armodafinil
- Where
- 55 sites in United States, Bulgaria and 2 more
- Volunteers
- 257 people
- Sponsor
- Cephalon
Bipolar Disorder, Depression
Acute Psychotherapy for Bipolar II Depression
This proposed study is designed to compare the efficacy of interpersonal and social rhythm therapy (IPSRT) alone to IPSRT plus medication as an acute treatment for bipolar II depression.
- Trial name
- NCT01133821
- Testing
- IPSRT plus quetiapine
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Holly Swartz
Acute Bipolar Depression
Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression
The purpose of this study is to compare the efficacy of quetiapine fumarate monotherapy with quetiapine fumarate in combination with lithium in the treatment of a major depressive episode in patients with bipolar disorder.
- Trial name
- QUALITY (NCT00883493)
- Testing
- Quetiapine fumarate XR, Lithium carbonate
- Where
- 24 sites in Argentina, Brazil and 7 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca
Bipolar II Disorder
Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II
1. The primary objective of this study is to examine the efficacy of quetiapine (Seroquel) in treatment of dysphoric hypomania in patients with Bipolar II disorder. 2.
- Trial name
- NCT00186043
- Testing
- Quetiapine/Seroquel
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Stanford University
Alcohol Dependence, Bipolar Disorder
Acamprosate vs. Placebo in Bipolar Alcoholics
To conduct a double-blind, randomized, placebo-controlled outpatient clinical trial of acamprosate in individuals with alcohol dependence and bipolar disorder who are also receiving mood stabilizing medication.
- Trial name
- NCT00466661
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Medical University of South Carolina
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder, Mixed Mania
Allopurinol Add-on Treatment for Refractory Mania
The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for treatment resistant mania and mixed mania.
- Conditions
- Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
- Trial name
- NCT00643123
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cedars-Sinai Medical Center
Bipolar Disorder, Depression
A Trial of SAMe for Treatment-Resistant Bipolar Depression
S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants.
- Conditions
- Bipolar Disorder, Depression, Bipolar Depression
- Trial name
- NCT00762268
- Testing
- SAMe
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mclean Hospital
Bipolar Disorder, Schizophrenia
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- NCT01487668
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development
Bipolar Depression
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
The goal of this project is to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, the project focuses on the importance of dopamine signaling in the process.
- Trial name
- NCT03902613
- Testing
- Lurasidone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New York State Psychiatric Institute
Bipolar I Disorder
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
This is an open-label, multi-center,12 week extension study designed to evaluate the longer term safety, tolerability and effectiveness of lurasidone, flexibly dosed, adjunctive to lithium or divalproex for the treatment of…
- Trial name
- PERSISTExt (NCT01575561)
- Testing
- Lurasidone
- Where
- 71 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar I Disorder
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with bipolar I disorder.
- Trial name
- NCT01059539
- Testing
- Cariprazine
- Where
- 35 sites in United States, Hungary and 2 more
- Volunteers
- 403 people
- Sponsor
- Forest Laboratories
Bipolar Disorder, Major Depressive Episode
Ketamine for Suicidality in Bipolar Depression
This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from bipolar depression.
- Conditions
- Bipolar Disorder, Major Depressive Episode, Suicidal Ideation
- Trial name
- NCT01944293
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder
N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder
We propose to conduct a double-blind placebo-controlled trial with a widely available and prototypical non-steroidal anti-inflammatory agent, aspirin, and an antioxidant agent, NAC, involving symptomatic Bipolar Disorder type I…
- Trial name
- SMRI-Bipolar (NCT01797575)
- Testing
- Aspirin, N-acetyl-cysteine (NAC), Sugar Pill
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- The University of Texas Health Science Center, Houston
Major Depressive Disorder, Bipolar Disorder
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
This study evaluates the efficacy of sleep deprivation treatment in accelerating antidepressant responses when administered during the first week of medications and augmenting a sustained response with chronobiological…
- Trial name
- NCT00581009
- Testing
- chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Bipolar Disorder
Simvastatin Augmentation of Lithium Treatment in Bipolar Depression
Primary Aim: To estimate the antidepressant efficacy of simvastatin versus placebo as an adjunct to lithium, valproate, and/or other atypical antipsychotic therapy among individuals with bipolar I disorder in a nonpsychotic major…
- Trial name
- NCT01665950
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital